Genomic instability in ulcerative colitis: A prerequisite for cancer in the inflammatory colon?

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 3, 2012, Pages 293-299

  Ekmektzoglou, Konstantinos ^a   Samelis, G ^b   Karagiannis, S ^c   Zografos, G ^b   Xanthos, T ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT HOSPITAL   (Greece)

^c Faculty of Nursing   (Greece)

Author keywords

Colorectal cancer; Genomic instability; Inflammation; Oxidative stress; Ulcerative colitis

Indexed keywords

MESALAZINE; NITRIC OXIDE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

CANCER PREVENTION; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLON POLYPOSIS; COLORECTAL CANCER; DNA METHYLATION; DYSPLASIA; EPIGENETICS; GENOMIC INSTABILITY; HUMAN; INFLAMMATION; MICROSATELLITE INSTABILITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; ULCERATIVE COLITIS;

CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; EPITHELIUM; GENOMIC INSTABILITY; HUMANS; PRECANCEROUS CONDITIONS;

EID: 84867318960     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. th ed. Philadelphia: Saunders, Elsevier, 2010: 1975-2014.
2. WILKS S. Lectures on pathological anatomy. London: Ongman, Brown, Green, Longman, & Roberts, 1859.
3. LOFTUS E.V. Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 2004, 126: 1504-17.
4. CROHN B.B., ROSENBERG H. The sigmoidoscopic picture of chronic ulcerative colitis. Am. J. Med. Sci., 1925, 170: 220-8.
5. SMITH R.A., VON ESCHENBACH A.C., WENDER R., LEVIN B., BYERS T., ROTHENBERGER D. et al.; ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA. Cancer. J. Clin., 2001, 51: 38-75; quiz 77-80.
6. EADEN J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther., 2004, 20: 24-30.
7. LEWIS J.D., DEREN J.J., LICHTENSTEIN G.R. Cancer risk in patients with inflammatory bowel disease. Gastroenterol. Clin. North. Am., 1999, 28: 459-77.
8. KULAYLAT M. N, DAYTON M.T. Ulcerative colitis and cancer. J. Surg. Oncol., 2010, 101: 706-12.
9. VIENNOT S., DELEPORTE A., MOUSSATA D., NANCEY S., FLOURIE B., REIMUND J.M. Colon cancer in inflammatory bowel disease: recent trends, questions and answers. Gastroenterol. Clin. Biol., 2009, 33: S190-201.
10. TRIANTAFILLIDIS J.K., NASIOULAS G., KOSMIDIS P.A. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer. Res., 2009, 29: 2727-37.
11. ULLMAN T. A, ITZKOWITZ S.H. Intestinal inflammation and cancer. Gastroenterology, 2011, 140: 1807-16.
12. CHEN R., RABINOVITCH P.S., CRISPIN D.A., EMOND M.J., BRONNER M.P., BRENTNALL T.A. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis., 2005, 26: 1513-9.
13. LOEB L.A. Mutator phenotype may be required for multistage carcino-genesis. Cancer. Res., 1991, 51: 3075-9.
14. KIM K., SHIBATA D. Methylation reveals a niche: stem cell succession in human colon crypts. Oncogene., 2002, 21: 5441-9.
15. THORSTEINSDOTTIR S., GUDJONSSON T., NIELSEN O.H., VAINER B., SEIDELIN J.B. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol., 2011, 8: 395-404.
16. RISQUES R.A., RABINOVITCH P.S., BRENTNALL T.A. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr. Opin. Gastroenterol., 2006, 22: 382-90.
17. SLATTERY M.L., SAMOWITZ W., HOFFMAN M., MA K.N., LEVIN T.R., NEUHAUSEN S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer. Epidemiol. Biomarkers. Prev., 2004, 13: 538-45.
18. RUTTER M., SAUNDERS B., WILKINSON K., RUMBLES S., SCHOFIELD G., KAMM M. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 2004, 126: 451-9.
19. GUPTA R.B., HARPAZ N., ITZKOWITZ S., HOSSAIN S., MATULA S., KORNBLUTH A. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology, 2007, 133: 1099-105.
20. WESTBROOK A.M., SZAKMARY A., SCHIESTL R.H. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat. Res., 2010, 705: 40-59.
21. COUSSENS L.M., RAYMOND W.W., BERGERS G., LAIGWEBSTER M., BEHRENDTSEN O., WERB Z. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes. Dev., 1999, 13: 1382-97.
22. CASORELLI I., PANNELLINI T., DE LUCA G., DEGAN P., CHIERA F., IAVARONE I. et al. The Mutyh base excision repair gene influences the inflammatory response in a mouse model of ulcerative colitis. PLoS. One, 2010, 5: e12070.
23. ROESSNER A., KUESTER D., MALFERTHEINER P., SCHNEIDERSTOCK R. Oxidative stress inulcerative colitis-associated carcinogenesis. Pathol. Res. Pract., 2008, 204: 511-24.
24. CAULFIELD J.L., WISHNOK J.S., TANNENBAUM S.R. Nitric oxideinduced deamination of cytosine and guanine in deoxynucleosides and oligonucleotides. J. Biol. Chem., 1998, 273: 12689-95.
25. NEDOSPASOV A.A. Is N2O3 the main nitrosating intermediate in aerated nitric oxide (NO) solutions in vivo? If so, where, when, and which one? J. Biochem. Mol. Toxicol., 2002, 16: 109-20.
26. ITZKOWITZ S.H., YIO X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver. Physiol., 2004, 287: G7-17.
27. WILLENBUCHER R.F., AUST D.E., CHANG C.G., ZELMAN S.J., FERRELL L.D., MOORE D.H. 2ND et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol., 1999, 154: 1825-30.
28. ITZKOWITZ S.H., HARPAZ N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology, 2004, 126: 1634-48.
29. XIE J., ITZKOWITZ S.H. Cancer in inflammatory bowel disease. World J. Gastroenterol., 2008, 14: 378-89.
30. REDSTON M.S., PAPADOPOULOS N., CALDAS C., KINZLER K.W., KERN S.E. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology, 1995, 108: 383-92.
31. TARMIN L., YIN J., HARPAZ N., KOZAM M., NOORDZIJ J., ANTONIO L.B. et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer. Res., 1995, 55: 2035-8.
32. AUST D.E., TERDIMAN J.P., WILLENBUCHER R.F., CHANG C.G., MOLINARO-CLARK A., BARETTON G.B. et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer, 2002, 94: 1421-7.
33. MORIN P.J., SPARKS A.B., KORINEK V., BARKER N., CLEVERS H., VOGELSTEIN B. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 1997, 275: 1787-90.
34. SVRCEK M., EL-BCHIRI J., CHALASTANIS A., CAPEL E., DUMONT S., BUHARD O. et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J. Clin. Oncol., 2007, 25: 4231-8.
35. ISSA J.P., AHUJA N., TOYOTA M., BRONNER M.P., BRENTNALL T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer. Res., 2001, 61: 3573-7.
36. ITZKOWITZ S.H., YOUNG E., DUBOIS D., HARPAZ N., BODIAN C., CHEN A. et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Gastroenterology, 1996, 110: 694-704.
37. RAPOZO D.C., GRINMANN A.B., CARVALHO A.T., DE SOUZA H.S., SOARES-LIMA S.C., DE ALMEIDA SIMAO T. et al. Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease. Int. J. Colorectal. Dis., 2009, 24: 1141-8.
38. CHEN R., RABINOVITCH P.S., CRISPIN D.A., EMOND M.J., KOPROWICZ K.M., BRONNER M.P. et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am. J. Pathol., 2003, 162: 665-72.
39. RABINOVITCH P.S., DZIADON S., BRENTNALL T.A., EMOND M.J., CRISPIN D.A., HAGGITT R.C. et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res., 1999, 59: 5148-53.
40. WILLENBUCHER R.F., ZELMAN S.J., FERRELL L.D., MOORE D.H. 2ND, WALDMAN F.M. Chromosomal alterations in ulcerative colitis related neoplastic progression. Gastroenterology, 1997, 113: 791-801.
41. ISHIGURO K., YOSHIDA T., YAGISHITA H., NUMATA Y., OKAYASU T. Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut, 2006, 55: 695-702.
42. MATSUMOTO N., YOSHIDA T., OKAYASU I. High epithelial and stromal genetic instability of chromosome 17 in ulcerative colitis-associated carcinogenesis. Cancer Res., 2003, 63: 6158-61.
43. SUZUKI H., HARPAZ N., TARMIN L., YIN J., JIANG H.Y., BELL J.D. et al. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res., 1994, 54: 4841-4.
44. THIBODEAU S.N., BREN G., SCHAID D. Microsatellite instability in cancer of the proximal colon. Science, 1993, 260: 816-19.
45. FUJIWARA I., YASHIRO M., KUBO N., MAEDA K., HIRAKAWA K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis. Colon. Rectum, 2008, 51: 1387-94.
46. TAHARA T., INOUE N., HISAMATSU T., KASHIWAGI K., TAKAISHI H., KANAI T. et al. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J. Gastroenterol. Hepatol., 2005, 20: 710-5.
47. LOVIG T., ANDERSEN S.N., CLAUSEN O.P., ROGNUM T.O. Microsatellite instability in long-standing ulcerative colitis. Scand. J. Gastroenterol., 2007, 42: 586-91.
48. TAKAHASHI S., KOJIMA Y., KINOUCHI Y., NEGORO K., TAKAGI S., AIHARA H. et al. Microsatellite instability and loss of heterozygosity in the nondysplastic colonic epithelium of ulcerative colitis. J. Gastroenterol., 2003, 38: 734-9.
49. KOLODNER R.D., MARSISCHKY G.T. Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev., 1999, 9: 89-96.
50. KUISMANEN S.A., HOLMBERG M.T., SALOVAARA R., DE LA CHAPELLE A., PELTOMAKI P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am. J. Pathol., 2000, 156: 1773-9.
51. FLEISHER A.S., ESTELLER M., HARPAZ N., LEYTIN A., RASHID A., XU Y. et al. Microsatellite instability in inflammatory bowel diseaseassociated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer. Res., 2000, 60: 4864-8.
52. LYNCH P.M. The hMSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. Surg. Oncol. Clin. N. Am., 2009, 18: 611-24.
53. LENGAUER C., KINZLER K.W., VOGELSTEIN B. Genetic instability in colorectal cancers. Nature, 1997, 386: 623-7.
54. RUBIN C.E., HAGGITT R.C., BURMER G.C., BRENTNALL T.A., STEVENS A.C., LEVINE D.S. et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastro-enterology, 1992, 103: 1611-20.
55. AUST D.E., WILLENBUCHER R.F., TERDIMAN J.P., FERRELL L.D., CHANG C.G., MOORE D.H. 2ND. et al. Chromosomal alterations in ulcerative colitis-related and sporadic colorectal cancers by comparative genomic hybridization. Hum. Pathol., 2000, 31: 109-14.
56. UMETANI N., SASAKI S., WATANABE T., SHINOZAKI M., MATSUDA K., ISHIGAMI H. et al. Genetic alterations in ulcerative colitisassociated neoplasia focusing on APC, K-ras gene and microsatellite instability. Jpn. J. Cancer. Res., 1999, 90: 1081-7.
57. BURMER G.C., RABINOVITCH P.S., HAGGITT R.C., CRISPIN D.A., BRENTNALL T.A., KOLLI V.R. et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology, 1992, 103: 1602-10.
58. YIN J., HARPAZ N., TONG Y., HUANG Y., LAURIN J., GREENWALD B.D. et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology, 1993, 104: 1633-39.
59. BRENTNALL T.A., CRISPIN D.A., RABINOVITCH P.S., HAGGITT R.C., RUBIN C.E., STEVENS A.C. et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology, 1994, 107: 369-78.
60. HUSSAIN S.P., AMSTAD P., RAJA K., AMBS S., NAGASHIMA M., BENNETT W.P. et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res., 2000, 60: 3333-7.
61. BORCHERS R., HEINZLMANN M., ZAHN R., WITTER K., MARTIN K., LOESCHKE K. et al. K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease. Scand. J. Gastroenterol., 2002, 37: 715-8.
62. LYDA M.H., NOFFSINGER A., BELLI J., FENOGLIO-PREISER C.M. Microsatellite instability and K-ras mutations in patients with ulcerative colitis. Hum. Pathol., 2000, 31: 665-71.
63. CARTWRIGHT C.A., COAD C.A., EGBERT B.M. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J. Clin. Invest., 1994, 93: 509-15.
64. RUSTGI A.K. c-src tyrosine kinase activity: a marker of dysplasia in ulcerative colitis. Gastroenterology, 1994, 107: 1565-6.
65. ITZKOWITZ S.H., MARSHALL A., KORNBLUTH A., HARPAZ N., MC HUGH J.B., AHNEN D. et al. Sialosyl-Tn antigen: initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology, 1995, 109: 490-7.
66. KARLEN P., YOUNG E., BROSTROM O., LOFBERG R., TRIBUKAIT B., OST K. et al. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology, 1998, 115: 1395-404.
67. KOIZUMI K., ALONSO S., MIYAKI Y., OKADA S., OGURA H., SHIIYA N. et al. Array-based identification of common DNA methylation alterations in ulcerative colitis. Int. J. Oncol., 2012, 40: 983-94.
68. TAHARA T., SHIBATA T., NAKAMURA M., OKUBO M., YAMASHITA H., YOSHIOKA D. et al. Association between polymorphisms in the XRCC1 and GST genes, and CpG island methylation status in colonic mucosa in ulcerative colitis. Virchows. Arch., 2011, 458: 205-11.
69. SANCHEZ J.A., DEJULIUS K.L., BRONNER M., CHURCH J.M., KALADY M.F. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Inflamm. Bowel. Dis., 2011, 17: 1966-70.
70. GARRITY-PARK M.M., LOFTUS E.V. JR., SANDBORN W.J., BRYANT S.C., SMYRK T.C. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am. J. Gastroenterol., 2010, 105: 1610-9.
71. MORIYAMA T., MATSUMOTO T., NAKAMURA S., JO Y., MIBU R., YAO T. et al. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis. Colon Rectum, 2007, 50: 1384-92.
72. SATO F., HARPAZ N., SHIBATA D., XU Y., YIN J., MORI Y. et al. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res., 2002, 62: 1148-51.
73. HSIEH C.J., KLUMP B., HOLZMANN K., BORCHARD F., GREGOR M., PORSCHEN R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res., 1998, 58: 3942-5.
74. WHEELER J.M., KIM H.C., EFSTATHIOU J.A., ILYAS M., MORTENSEN N.J., BODMER W.F. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut, 2001, 48: 367-71.
75. JAWAD N., DIREKZE N., LEEDHAM S.J. Inflammatory bowel disease and colon cancer. Recent. Results. Cancer Res., 2011, 185: 99-115.
76. BAUMGART D.C. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when? Dig. Dis., 2011, 29: S32-5.
77. SCHMIDT C., BIELECKI C., FELBER J., STALLMACH A. Surveillance strategies in inflammatory bowel disease. Minerva. Gastroenterol. Dietol., 2010, 56: 189-201.
78. KIESSLICH R. Chromoendoscopy: what is its true value for ulcerative colitis surveillance? Dig. Dis., 2010, 28: 445-51.
79. ULLMAN T.A. Should chromoendoscopy be the standard of care in ulcerative colitis dysplasia surveillance? Gastroenterol. Hepatol. (NY), 2010, 6: 616-20.
80. HLAVATY T., HUORKA M., KOLLER T., ZITA P., KRESANOVA E., RYCHLY B. et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur. J. Gastroenterol. Hepatol., 2011, 23: 680-9.
81. MATTAR M.C., LOUGH D., PISHVAIAN M.J., CHARABATY A. Current management of inflammatory bowel disease and colorectal cancer. Gastro-intest. Cancer. Res., 2011, 4: 53-61.